1. Home
  2. CRSP vs ST Comparison

CRSP vs ST Comparison

Compare CRSP & ST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • ST
  • Stock Information
  • Founded
  • CRSP 2013
  • ST 1916
  • Country
  • CRSP Switzerland
  • ST United States
  • Employees
  • CRSP N/A
  • ST N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • ST Industrial Machinery/Components
  • Sector
  • CRSP Health Care
  • ST Industrials
  • Exchange
  • CRSP Nasdaq
  • ST Nasdaq
  • Market Cap
  • CRSP 5.6B
  • ST 4.7B
  • IPO Year
  • CRSP 2016
  • ST 2010
  • Fundamental
  • Price
  • CRSP $71.48
  • ST $30.73
  • Analyst Decision
  • CRSP Buy
  • ST Buy
  • Analyst Count
  • CRSP 18
  • ST 13
  • Target Price
  • CRSP $72.59
  • ST $34.46
  • AVG Volume (30 Days)
  • CRSP 2.6M
  • ST 1.3M
  • Earning Date
  • CRSP 11-04-2025
  • ST 11-03-2025
  • Dividend Yield
  • CRSP N/A
  • ST 1.57%
  • EPS Growth
  • CRSP N/A
  • ST 1246.54
  • EPS
  • CRSP N/A
  • ST 0.74
  • Revenue
  • CRSP $38,050,000.00
  • ST $3,745,159,000.00
  • Revenue This Year
  • CRSP N/A
  • ST N/A
  • Revenue Next Year
  • CRSP $388.50
  • ST $3.53
  • P/E Ratio
  • CRSP N/A
  • ST $41.29
  • Revenue Growth
  • CRSP N/A
  • ST N/A
  • 52 Week Low
  • CRSP $30.04
  • ST $17.32
  • 52 Week High
  • CRSP $73.95
  • ST $36.64
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 66.62
  • ST 43.57
  • Support Level
  • CRSP $67.41
  • ST $30.00
  • Resistance Level
  • CRSP $73.95
  • ST $31.61
  • Average True Range (ATR)
  • CRSP 3.46
  • ST 0.82
  • MACD
  • CRSP 0.87
  • ST 0.00
  • Stochastic Oscillator
  • CRSP 76.46
  • ST 36.50

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About ST Sensata Technologies Holding plc

Sensata Technologies is a global supplier of sensors for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.

Share on Social Networks: